Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Short Interest Down 36.9% in March

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) was the recipient of a large decrease in short interest during the month of March. As of March 15th, there was short interest totalling 1,250,000 shares, a decrease of 36.9% from the February 28th total of 1,980,000 shares. Based on an average trading volume of 2,640,000 shares, the days-to-cover ratio is presently 0.5 days. Approximately 2.6% of the company’s shares are sold short.

Cardio Diagnostics Stock Performance

Shares of NASDAQ:CDIO traded down $0.03 during mid-day trading on Friday, reaching $0.38. 1,509,670 shares of the company were exchanged, compared to its average volume of 2,533,523. Cardio Diagnostics has a 1 year low of $0.19 and a 1 year high of $1.77. The firm’s 50-day simple moving average is $0.48 and its 200 day simple moving average is $0.48.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC grew its stake in shares of Cardio Diagnostics by 97.6% in the fourth quarter. Geode Capital Management LLC now owns 364,387 shares of the company’s stock valued at $334,000 after buying an additional 179,978 shares in the last quarter. Two Sigma Securities LLC acquired a new position in Cardio Diagnostics in the 4th quarter valued at about $48,000. Jane Street Group LLC purchased a new stake in Cardio Diagnostics during the fourth quarter worth about $103,000. Finally, Millennium Management LLC acquired a new stake in shares of Cardio Diagnostics during the fourth quarter worth about $236,000. 8.06% of the stock is currently owned by institutional investors and hedge funds.

Cardio Diagnostics Company Profile

Cardio Diagnostics Holdings, Inc develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease.